Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is demonstrating promising data in initial human trials . Ongoing research suggests https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/